revenue growth

Magnificent Seven stocks underperform S&P 500 in 2026 amid AI spending concerns, but valuations compress to market averages. Nvidia emerges as standout opportunity at sub-21 forward P/E with fastest group growth.

ANI Pharma posts record $883M revenue (up 44% YoY) with rare disease growth driving performance; insider sells 4,772 shares amid $1B+ 2026 guidance.

Rosen Law Firm urges monday.com investors to meet May 2026 deadline in securities fraud lawsuit alleging false growth claims.

Paul Mueller Company reported robust 2025 earnings with Q4 sales up 33.6% and full-year net income climbing 16.9%, supported by a surging $243.6M backlog.

Micron begins mass production of HBM4 memory for Nvidia's Vera Rubin GPU, with 196% revenue growth and 41% net margins, signaling structural AI infrastructure demand through 2030.

$NVDA trading at lowest valuation multiples since AI boom began, with P/E of 34.95x despite 65% YoY revenue growth, creating potential buying opportunity.

Winnebago beats Q2 earnings with 42% profit growth, but stock falls 7% as investors worry gains stem from pricing, not volume growth, amid sector headwinds.

Marvell Technology reports 21% data center revenue growth with 40% growth forecast for fiscal 2027. Trading at 24x forward earnings, analysts see 50% upside potential, though data center spending risks remain.

Meta targets $9 trillion valuation by 2031, requiring 43% annual revenue growth and 494% stock price increase. Heavy AI investments questioned by analysts.

Globavend Holdings ($GVH) surged 37% after-hours on CEO control disclosure and strong 2025 financials showing 42.5% revenue growth, though stock remains down 99% over 12 months.

Sanuwave Health reported record 2025 revenues of $44.1M, up 35% YoY, driven by strong UltraMist system sales and improved margins.

Wrap Technologies reports 15% full-year revenue growth to $5.2M and targets 100% growth in 2026 through federal market entry and international expansion.

Serve Robotics scaled fleet 20x to 2,000 robots while revenue jumped to $25.9M. Stock down 61% from December peak despite growth trajectory.

Adaptive Biotechnologies COO Julie Rubinstein sold 179,703 shares for $2.37M via pre-arranged tax plan as company posts strong 55% revenue growth.

Softcare Ltd. reports 25% revenue growth and 27% profit increase post-IPO, validating emerging markets strategy and regional manufacturing advantages.

Lumexa Imaging reported 7.9% Q4 revenue growth and 18.6% Adjusted EBITDA expansion, with full-year 2025 revenues of $1.023 billion. The company reiterated 2026 guidance.

Oracle's 2019 multicloud strategy with AWS, Azure, and Google Cloud is driving 500% database revenue growth as AI adoption accelerates across enterprises.

Arm Holdings surges 16% unveiling AI-focused CPU projected to generate $15 billion revenue by 2031, with major tech firms committed to evaluation and deployment.

$DPRO crashed 21.8% after Q4 earnings disappointed, but record revenue growth and analyst Buy ratings suggest the selloff may be overdone.

The RealReal's CFO sold 51,585 shares ($479K) via automatic tax withholding, yet stock surged 46% annually on 15% revenue growth and margin expansion.